Immunohistochemical Analysis of c-yes and c-erbB-2 Oncogene Products and p53 Tumor Suppressor Protein in Canine Mammary Tumors

Abstract

In order to evaluate the involvement of c-yes and c-erbB-2 oncogene products, and p53 tumor suppressor protein in canine mammary neoplastic lesions, sections of archived paraffin-embedded samples of 79 mammary tumors were analyzed immunohistochemically using antibodies against human c-yes p62 and c-erbB-2 products and p53. These 79 tumors were divided into 2 groups: 32 benign (2 adenosis, 7 simple adenomas, 14 complex adenomas, and 9 benign mixed mammary tumors) and 47 malignant tumors (26 simple adenocarcinomas, 7 complex adenocarcinomas, 5 solid carcinomas, 2 sclerosing carcinomas, 6 malignant mixed mammary tumors, and 1 malignant myoepithelioma). As a result of immunostaining, 40.6% (13/32) of the benign tumors and 21.3% (10/47) of the malignant tumors expressed the c-Yes oncogene product, ErbB-2 expression was detected in 50% (16/32) of the benign tumors and in 19.1% (9/47) of the malignant tumors. P53 expression was detected in 16% (4/25) of the benign tumors and in 30.6% (11/36) of the malignant tumors. Co-expression of c-Yes and ErbB-2, ErbB-2 and p53, and all 3 products was detected in 6, 1 and 7 tumors, respectively.

Expression of p-53 and Cox-2 Genes as Tumour Markers in Spontaneous Canine Mammary Tumours

“…The p53 mutation used as a risk factor for increased risk of recurrence and death from breast cancer independent of tumour size, hormone receptor levels (Iacopetta et al, 1998). The results of the present study are in agreement with other researcher (Rungzipipat et al, 1999), who also observed p53 overexpression in different canine tumours. Determination of the p53 status in canine cancer patients helped in investigating the role of p53 in mammary tumour formation and its progression (Veldhoen et al, 1999).…”

12_Prospective Study of Tumor Markers as Prognostic Factors in the Histopathological Differential Diagnosis of Mammary Gland Neoplasms in Female Canines

“…In our study, the highest expression of p53 was observed in complex carcinomas and in 1 st and 2 nd grade malignant tumors. These results are consistent with the results obtained by Rungsipipata (1999), who found the highest levels of p53 expression in simple and complex carcinomas and also showed expression of this protein in adenomas (16%) (Rungspipata, 1999). Rodo (2007) obtained results on the expression of p53 , stating that there is a positive correlation between proliferative activity and the number of cells expressing p53 protein (Rodo, 2007).…”

Multiple mammary tumours in a bitch: analysis of mitotic index, AgNOR count and c-erbB2 expression status: a case report

“…In the present case the tumours T-2 and T-3 were positive for c-erbB2 overexpression while T-1 was negative. Both T-2 and T-3 consisted of neoplastic cells of epithelial origin and it has been reported that c-erbB2 overexpression is mostly restricted to mammary tumours of epithelial origin (Yakota et al, 1986;Rungsipipat et al, 1999;Kumar et al, 2009). Overexpression of c-erbB2 has been correlated with poor prognosis of human breast cancers by many researchers (Yakota et al, 1986;Bruman et al, 1990).…”